Abbott Diagnostics Exhibits POC Diagnostics Solutions at AACC
|
By LabMedica International staff writers Posted on 05 Aug 2019 |

Image: The ID NOW isothermal system for the qualitative detection of infectious diseases (Photo courtesy of Abbott Diagnostics).
Abbott Diagnostics (Lake Bluff, IL, USA) exhibited its range of rapid Point-of-Care (POC) diagnostics solutions at the 71st AACC Annual Scientific Meeting & Clinical Lab Expo held in Anaheim, California, USA. The annual event held by the American Association for Clinical Chemistry (AACC) showcased the cutting-edge science and technology shaping the future of laboratory medicine.
At AACC 2019, Abbott exhibited ID NOW, a rapid, instrument-based, isothermal system for the qualitative detection of infectious diseases. The ID NOW isothermal nucleic acid amplification technology provides molecular results in just minutes, allowing users to make effective clinical decisions sooner. ID NOW is significantly faster than other molecular methods and more accurate than conventional rapid tests and can have a positive impact in any healthcare setting.
Abbott also showcased its Afinion 2 Analyzer, a compact, rapid, multi-assay analyzer that provides valuable near patient testing at the POC. Designed to enable simple and fast on-the-spot testing, regardless of the sample type, the Afinion System makes it fast and easy to test quantitative determinations of HbA1c, Lipid Panel, ACR, and CRP. By delivering accurate results during patient consultation, it eliminates the need to send patients to the lab or spend time tracking down their results for improved patient management.
Abbott also demonstrated its RALS POC Data management system, which provides immediate and remote access to patient and quality control results from the POCT devices being used. Unlike data management solutions that use a device-specific data manager between the device and their system, the RALS System can manage all devices, all patient results, all operators, all consumables and all reports —from a single-system solution.
At AACC 2019, Abbott exhibited ID NOW, a rapid, instrument-based, isothermal system for the qualitative detection of infectious diseases. The ID NOW isothermal nucleic acid amplification technology provides molecular results in just minutes, allowing users to make effective clinical decisions sooner. ID NOW is significantly faster than other molecular methods and more accurate than conventional rapid tests and can have a positive impact in any healthcare setting.
Abbott also showcased its Afinion 2 Analyzer, a compact, rapid, multi-assay analyzer that provides valuable near patient testing at the POC. Designed to enable simple and fast on-the-spot testing, regardless of the sample type, the Afinion System makes it fast and easy to test quantitative determinations of HbA1c, Lipid Panel, ACR, and CRP. By delivering accurate results during patient consultation, it eliminates the need to send patients to the lab or spend time tracking down their results for improved patient management.
Abbott also demonstrated its RALS POC Data management system, which provides immediate and remote access to patient and quality control results from the POCT devices being used. Unlike data management solutions that use a device-specific data manager between the device and their system, the RALS System can manage all devices, all patient results, all operators, all consumables and all reports —from a single-system solution.
Latest AACC 2019 News
- Instrumentation Laboratory Presents New IVD Testing System
- Quidel Welcomes Newest Member of Triage Family
- ERBA Mannheim Unveils Next-Generation Automation
- Roche Demonstrates How Health Networks Are Driving Change in Labs and Beyond
- BioMérieux Spotlights Diagnostic Solutions in Use of Antibiotics
- Thermo Shows New Clinical Innovations
- Randox Launches New Innovations
- Streck Introduces Three New Antibiotic Resistance Detection Kits
- EKF Diagnostics Highlights Assay for Diabetes Patient Monitoring
- Sysmex America Exhibits New Products, Automation and Quality Solutions
- BBI Solutions Showcases Mobile Solutions Capabilities at AACC 2019
- MedTest Dx Releases New Product Line for Drugs of Abuse Testing
- Mesa Biotech Launches Molecular Test System at AACC 2019
- Ortho Clinical Diagnostics Highlights Groundbreaking Lab Technology
- Beckman Coulter Demonstrates Latest Innovations in Lab Medicine
- Orion Diagnostica Showcases Range of Products in Anaheim
Channels
Clinical Chemistry
view channel
Blood Proteins Linked to Mortality Risk and Biological Aging Across Organ Systems
Older adults of the same chronological age can differ markedly in health, chronic disease burden, and resilience. Biological age aims to capture these differences by reflecting how rapidly the body and... Read more
Two-Step Blood Test Improves Specificity for Alzheimer’s Diagnosis
Early Alzheimer’s disease can be difficult to identify before more severe cognitive symptoms emerge. Blood tests measuring phosphorylated tau protein p-tau217 may help detect disease-related changes, but... Read moreMolecular Diagnostics
view channel
Tumor and Immune Biomarkers Linked to Treatment Response in T-Cell Lymphoma
T-follicular helper cell lymphoma (TFHL) is a subtype of peripheral T-cell lymphoma associated with poor prognosis and limited treatment options after relapse. Its molecular abnormalities include frequent... Read more
Blood MRD Testing Aids Risk Analysis in Bladder and Other Cancers
Natera (Austin, TX, USA) presented findings from 25 abstracts, including nine oral presentations, at the ESMO Congress 2026 in Madrid. The research examined circulating tumor DNA (ctDNA) testing for molecular... Read moreHematology
view channel
Genetic Testing Offers Opportunities for Earlier Blood Disorder Carrier Identification
Inherited hemoglobin disorders can affect oxygen transport, yet individuals who carry only a trait may remain unaware of their status. People with sickle cell trait or beta-thalassemia trait often have... Read more
New Risk-Stratification Tool Predicts Relapse After Blinatumomab in Childhood ALL
Acute lymphoblastic leukemia in children and young people requires careful assessment of relapse risk, particularly as treatment approaches move beyond standard chemotherapy. Traditional relapse predictors... Read moreImmunology
view channel
Prototype Point-of-Care Lateral Flow Test Aims to Improve Neonatal Sepsis Triage
Sepsis in newborns and young infants remains a major clinical challenge, particularly in low- and middle-income countries. An estimated 2.3 million newborns die each year, with sepsis contributing substantially... Read more
Immune and Inflammatory Markers May Help Assess CAR T-Cell Complication Risk
Cytokine release syndrome (CRS) can occur after chimeric antigen receptor (CAR) T-cell therapy in patients with autoimmune disease. Identifying which patients are more likely to develop this complication... Read moreMicrobiology
view channel
Decentralized Laboratory Network Improves Detection of Viral Hemorrhagic Fevers in Guinea
Viral hemorrhagic fevers remain a major diagnostic challenge in West Africa because their early symptoms can resemble those of other febrile illnesses. The 2014–2016 Ebola epidemic underscored the need... Read more
Molecular Panel Gains WHO Emergency Use Listing to Support Ebola Outbreak Response
The ongoing Ebola Bundibugyo outbreak in the Democratic Republic of the Congo and neighboring countries has become one of the largest outbreaks of this Ebola virus species recorded to date.... Read morePathology
view channel
AI Pathology Approach Closely Aligns With Breast Cancer Genomic Risk Classification
In early-stage breast cancer, precision oncology relies on biological information to guide personalized treatment decisions. Because access to tissue-based genomic testing may be limited, there is growing... Read more
Roche Launches Automated Test to Support Mesothelioma Differential Diagnosis
Mesothelioma is a rare, deadly cancer that forms in the tissue lining many internal organs. Most patients are diagnosed late, with median overall survival reported at 12 to 18 months. Differential diagnosis... Read more
Digital Pathology Test Stratifies Recurrence Risk in Early Breast Cancer
In hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer, accurate recurrence-risk assessment helps guide treatment decisions. However, individual risks... Read more
AI Pathology Tool Predicts DNA Repair Deficiency in High-Grade Serous Ovarian Cancer
High-grade serous tubo-ovarian carcinoma is an aggressive cancer arising in the ovaries or fallopian tubes. Some tumors exhibit homologous recombination deficiency (HRD), a feature reflecting impaired DNA repair.... Read moreTechnology
view channel
Microfluidic Assay Predicts Treatment Response in Pediatric Leukemia
Acute lymphoblastic leukemia (ALL) is a rapidly developing blood cancer that can disrupt production of mature infection-fighting white blood cells within months. More than 120,000 people in the U.... Read more
AI Models Use Routine Blood Tests and Health Records to Predict Cancer Risk
Cancer screening programs cover only certain cancers and often rely on broad eligibility criteria, limiting individualized risk assessment across multiple cancer types. Routine health data, including blood... Read moreIndustry
view channel
CE-Marked IVD Sequencing Platform Launches Across Ten EU Countries
Clinical laboratories using sequencing in regulated diagnostic workflows need systems that support clearly defined processes and documentation. In Europe, meeting applicable EU IVDR requirements also means... Read more








